Literature DB >> 22080182

Exposed or not exposed? Exploring exposure classification in studies using administrative data to investigate outcomes following medication use during pregnancy.

Luke E Grzeskowiak1, Andrew L Gilbert, Janna L Morrison.   

Abstract

PURPOSE: The aim of this systematic review was to examine and compare differences in the way medication exposures are classified in studies using linked administrative data to investigate outcomes following medication use during pregnancy. This was undertaken with a focus on studies investigating specific neonatal outcomes following prenatal exposure to selective serotonin reuptake inhibitors (SSRIs).
METHODS: We searched Medline and Embase to identify studies that used linked administrative data to investigate specific neonatal outcomes (congenital malformations, birth weight, gestational age) following prenatal exposure to SSRIs.
RESULTS: Key factors such as dose, duration and timing of exposure were inconsistently addressed in the studies identified. In addition, there was a great deal of variability in the way medication exposures were classified and how women who stop taking their medication before or during early pregnancy are handled in analyses. Furthermore, there are issues in assuming how and when women who receive a dispensing for a medication actually take it during pregnancy. This creates a great deal of uncertainty around medication exposure during pregnancy in studies using linked administrative data, potentially resulting in biased risk estimates.
CONCLUSIONS: There is a need for greater focus on determining the most effective and accurate way of using linked administrative data to investigate outcomes following medication use during pregnancy in an effort to minimise potential biases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22080182     DOI: 10.1007/s00228-011-1154-9

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  30 in total

1.  Do pregnant women report use of dispensed medications?

Authors:  C Olesen; C Søndergaard; N Thrane; G L Nielsen; L de Jong-van den Berg; J Olsen
Journal:  Epidemiology       Date:  2001-09       Impact factor: 4.822

2.  Systematic identification of drugs that cause birth defects--a new opportunity.

Authors:  Allen A Mitchell
Journal:  N Engl J Med       Date:  2003-12-25       Impact factor: 91.245

Review 3.  Methodological issues in the epidemiological study of the teratogenicity of drugs.

Authors:  Bengt A J Källén
Journal:  Congenit Anom (Kyoto)       Date:  2005-06       Impact factor: 1.409

4.  Using observational cohort data for studying drug effects on pregnancy outcome--methodological considerations.

Authors:  Christof Schaefer; Asher Ornoy; Maurizio Clementi; Reinhard Meister; Corinna Weber-Schoendorfer
Journal:  Reprod Toxicol       Date:  2008-06-07       Impact factor: 3.143

Review 5.  Assessing the safety of drugs in pregnancy: the role of prospective cohort studies.

Authors:  C Irl; J Hasford
Journal:  Drug Saf       Date:  2000-03       Impact factor: 5.606

6.  Population-based linkage of health records in Western Australia: development of a health services research linked database.

Authors:  C D Holman; A J Bass; I L Rouse; M S Hobbs
Journal:  Aust N Z J Public Health       Date:  1999-10       Impact factor: 2.939

7.  Selective serotonin reuptake inhibitors and adverse pregnancy outcomes.

Authors:  Shi Wu Wen; Qiuying Yang; Peter Garner; William Fraser; Olufemi Olatunbosun; Carl Nimrod; Mark Walker
Journal:  Am J Obstet Gynecol       Date:  2006-04       Impact factor: 8.661

8.  Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a population-based cohort study from the Netherlands.

Authors:  Marian K Bakker; Pieternel Kölling; Paul B van den Berg; Hermien E K de Walle; Lolkje T W de Jong van den Berg
Journal:  Br J Clin Pharmacol       Date:  2007-10-22       Impact factor: 4.335

9.  Paroxetine in the first trimester and the prevalence of congenital malformations.

Authors:  J Alexander Cole; Sara A Ephross; Irene S Cosmatos; Alexander M Walker
Journal:  Pharmacoepidemiol Drug Saf       Date:  2007-10       Impact factor: 2.890

10.  Drug use during pregnancy in Sweden - assessed by the Prescribed Drug Register and the Medical Birth Register.

Authors:  Olof Stephansson; Fredrik Granath; Tobias Svensson; Bengt Haglund; Anders Ekbom; Helle Kieler
Journal:  Clin Epidemiol       Date:  2011-02-01       Impact factor: 4.790

View more
  19 in total

1.  Methodological challenges in using routinely collected health data to investigate long-term effects of medication use during pregnancy.

Authors:  Luke E Grzeskowiak; Andrew L Gilbert; Janna L Morrison
Journal:  Ther Adv Drug Saf       Date:  2013-02

2.  Safe Expectations: Current State and Future Directions for Medication Safety in Pregnancy Research.

Authors:  Mollie E Wood; Susan E Andrade; Sengwee Toh
Journal:  Clin Ther       Date:  2019-09-25       Impact factor: 3.393

3.  Risks of 23 specific malformations associated with prenatal exposure to 10 antiepileptic drugs.

Authors:  Pierre-Olivier Blotière; Fanny Raguideau; Alain Weill; Elisabeth Elefant; Isabelle Perthus; Véronique Goulet; Florence Rouget; Mahmoud Zureik; Joël Coste; Rosemary Dray-Spira
Journal:  Neurology       Date:  2019-06-12       Impact factor: 9.910

4.  Impact of serotonin reuptake inhibitor use on breast milk supply in mothers of preterm infants: a retrospective cohort study.

Authors:  Luke E Grzeskowiak; Catherine Leggett; Lynn Costi; Claire T Roberts; Lisa H Amir
Journal:  Br J Clin Pharmacol       Date:  2018-04-14       Impact factor: 4.335

5.  Validation of maternal recall of early pregnancy medication exposure using prospective diary data.

Authors:  Alexandra C Sundermann; Katherine E Hartmann; Sarah H Jones; Eric S Torstenson; Digna R Velez Edwards
Journal:  Ann Epidemiol       Date:  2016-12-09       Impact factor: 3.797

6.  Validation of an algorithm to estimate gestational age in electronic health plan databases.

Authors:  Qian Li; Susan E Andrade; William O Cooper; Robert L Davis; Sascha Dublin; Tarek A Hammad; Pamala A Pawloski; Simone P Pinheiro; Marsha A Raebel; Pamela E Scott; David H Smith; Inna Dashevsky; Katherine Haffenreffer; Karin E Johnson; Sengwee Toh
Journal:  Pharmacoepidemiol Drug Saf       Date:  2013-01-21       Impact factor: 2.890

7.  Adherence to and Persistence with Antidepressant Medication during Pregnancy: Does It Differ by the Class of Antidepressant Medication Prescribed?

Authors:  Kamala Adhikari; Scott B Patten; Sangmin Lee; Amy Metcalfe
Journal:  Can J Psychiatry       Date:  2018-09-25       Impact factor: 4.356

8.  Pregnancy and Delivery Outcomes Following Benzodiazepine Exposure: A Systematic Review and Meta-analysis.

Authors:  Sophie Grigoriadis; Lisa Graves; Miki Peer; Lana Mamisashvili; Myuri Ruthirakuhan; Parco Chan; Mirna Hennawy; Supriya Parikh; Simone Natalie Vigod; Cindy-Lee Dennis; Meir Steiner; Cara Brown; Amy Cheung; Hiltrud Dawson; Neil Rector; Melanie Guenette; Margaret Richter
Journal:  Can J Psychiatry       Date:  2020-03-09       Impact factor: 4.356

9.  Actual Use of Medications Prescribed During Pregnancy: A Cross-Sectional Study Using Data from a Population-Based Congenital Anomaly Registry.

Authors:  Linda de Jonge; Hermien E K de Walle; Lolkje T W de Jong-van den Berg; Irene M van Langen; Marian K Bakker
Journal:  Drug Saf       Date:  2015-08       Impact factor: 5.606

Review 10.  Prenatal exposure to antidepressants and persistent pulmonary hypertension of the newborn: systematic review and meta-analysis.

Authors:  Sophie Grigoriadis; Emily H Vonderporten; Lana Mamisashvili; George Tomlinson; Cindy-Lee Dennis; Gideon Koren; Meir Steiner; Patricia Mousmanis; Amy Cheung; Lori E Ross
Journal:  BMJ       Date:  2014-01-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.